ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

Thermon Group Holdings (THR) PT Raised to $22 at Jefferies; Reiterates Buy

May 25, 2017 9:50 AM EDT

Jefferies raised its price target on Thermon Group Holdings (NYSE: THR) to $22.00 (from $21.00) while maintaining a Buy rating. THR reported adjusted EPS of $0.10, which was lower than the consensus estimate of $0.13.

THR project dashboard has a pipeline of 850 projects worth ~$1b. The... More